From the bakery to the brain business

Developing inducible yeast models of human neurodegenerative disorders

Alejandro Ocampo, Antonio Barrientos

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In the last decade, the budding yeast Saccharomyces cerevisiae has been used as a model system to study the mechanisms of the human aging process and of age-associated neurodegenerative disorders such as Parkinson's, Huntington's, Alzheimer's, and amyotrophic lateral sclerosis. S. cerevisiae is a facultative aerobic, unicellular yeast, and despite their simplicity, yeast cells possess most of the same basic cellular machinery as neurons in the brain, including pathways required for protein homeostasis and energy metabolism. The power of yeast genetics and the use of high-throughput screening technologies have provided important clues concerning the pathophysiology of these disorders and the identification of candidate therapeutic targets and drugs. The yeast models are based on the expression of human disease proteins in yeast and recapitulate some of the cytotoxic features observed in patients. However, the currently available models mostly suffer from high-level protein expression that results in acute cytotoxicity, and from metabolic constraints when the models are based on extensively used, strong, galactose-inducible promoters. The models would increase their significance if they were based on continuous and tightly regulated gene expression systems for both activation and levels of expression. This would allow for more chronic cytotoxicity that better simulates the timing of events that occur during disease progression. Additionally, the use of metabolism-independent inducers would allow for the study of cell toxicities under conditions where the cells are forced to exclusively respire, thus more reliably modeling the highly oxidative neuronal metabolism. Here we have constructed yeast models of Huntington's disease based on the expression, under the control of different promoters, of the first exon of the huntingtin-containing polyglutamine tracts of both wild-type and mutant lengths. The different models are compared and evaluated.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalBioTechniques
Volume45
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Bakeries
Neurodegenerative Diseases
Yeast
Brain
Yeasts
Industry
Saccharomyces cerevisiae
Saccharomycetales
Fungal Proteins
Cytotoxicity
Huntington Disease
Amyotrophic Lateral Sclerosis
Metabolism
Galactose
Energy Metabolism
Disease Progression
Exons
Proteins
Homeostasis
Technology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biotechnology

Cite this

From the bakery to the brain business : Developing inducible yeast models of human neurodegenerative disorders. / Ocampo, Alejandro; Barrientos, Antonio.

In: BioTechniques, Vol. 45, No. 4, 01.10.2008, p. 7-13.

Research output: Contribution to journalArticle

@article{755ca374864145c0b1a1544b5e30fed8,
title = "From the bakery to the brain business: Developing inducible yeast models of human neurodegenerative disorders",
abstract = "In the last decade, the budding yeast Saccharomyces cerevisiae has been used as a model system to study the mechanisms of the human aging process and of age-associated neurodegenerative disorders such as Parkinson's, Huntington's, Alzheimer's, and amyotrophic lateral sclerosis. S. cerevisiae is a facultative aerobic, unicellular yeast, and despite their simplicity, yeast cells possess most of the same basic cellular machinery as neurons in the brain, including pathways required for protein homeostasis and energy metabolism. The power of yeast genetics and the use of high-throughput screening technologies have provided important clues concerning the pathophysiology of these disorders and the identification of candidate therapeutic targets and drugs. The yeast models are based on the expression of human disease proteins in yeast and recapitulate some of the cytotoxic features observed in patients. However, the currently available models mostly suffer from high-level protein expression that results in acute cytotoxicity, and from metabolic constraints when the models are based on extensively used, strong, galactose-inducible promoters. The models would increase their significance if they were based on continuous and tightly regulated gene expression systems for both activation and levels of expression. This would allow for more chronic cytotoxicity that better simulates the timing of events that occur during disease progression. Additionally, the use of metabolism-independent inducers would allow for the study of cell toxicities under conditions where the cells are forced to exclusively respire, thus more reliably modeling the highly oxidative neuronal metabolism. Here we have constructed yeast models of Huntington's disease based on the expression, under the control of different promoters, of the first exon of the huntingtin-containing polyglutamine tracts of both wild-type and mutant lengths. The different models are compared and evaluated.",
author = "Alejandro Ocampo and Antonio Barrientos",
year = "2008",
month = "10",
day = "1",
doi = "10.2144/000112746",
language = "English",
volume = "45",
pages = "7--13",
journal = "BioTechniques",
issn = "0736-6205",
publisher = "Eaton Publishing Company",
number = "4",

}

TY - JOUR

T1 - From the bakery to the brain business

T2 - Developing inducible yeast models of human neurodegenerative disorders

AU - Ocampo, Alejandro

AU - Barrientos, Antonio

PY - 2008/10/1

Y1 - 2008/10/1

N2 - In the last decade, the budding yeast Saccharomyces cerevisiae has been used as a model system to study the mechanisms of the human aging process and of age-associated neurodegenerative disorders such as Parkinson's, Huntington's, Alzheimer's, and amyotrophic lateral sclerosis. S. cerevisiae is a facultative aerobic, unicellular yeast, and despite their simplicity, yeast cells possess most of the same basic cellular machinery as neurons in the brain, including pathways required for protein homeostasis and energy metabolism. The power of yeast genetics and the use of high-throughput screening technologies have provided important clues concerning the pathophysiology of these disorders and the identification of candidate therapeutic targets and drugs. The yeast models are based on the expression of human disease proteins in yeast and recapitulate some of the cytotoxic features observed in patients. However, the currently available models mostly suffer from high-level protein expression that results in acute cytotoxicity, and from metabolic constraints when the models are based on extensively used, strong, galactose-inducible promoters. The models would increase their significance if they were based on continuous and tightly regulated gene expression systems for both activation and levels of expression. This would allow for more chronic cytotoxicity that better simulates the timing of events that occur during disease progression. Additionally, the use of metabolism-independent inducers would allow for the study of cell toxicities under conditions where the cells are forced to exclusively respire, thus more reliably modeling the highly oxidative neuronal metabolism. Here we have constructed yeast models of Huntington's disease based on the expression, under the control of different promoters, of the first exon of the huntingtin-containing polyglutamine tracts of both wild-type and mutant lengths. The different models are compared and evaluated.

AB - In the last decade, the budding yeast Saccharomyces cerevisiae has been used as a model system to study the mechanisms of the human aging process and of age-associated neurodegenerative disorders such as Parkinson's, Huntington's, Alzheimer's, and amyotrophic lateral sclerosis. S. cerevisiae is a facultative aerobic, unicellular yeast, and despite their simplicity, yeast cells possess most of the same basic cellular machinery as neurons in the brain, including pathways required for protein homeostasis and energy metabolism. The power of yeast genetics and the use of high-throughput screening technologies have provided important clues concerning the pathophysiology of these disorders and the identification of candidate therapeutic targets and drugs. The yeast models are based on the expression of human disease proteins in yeast and recapitulate some of the cytotoxic features observed in patients. However, the currently available models mostly suffer from high-level protein expression that results in acute cytotoxicity, and from metabolic constraints when the models are based on extensively used, strong, galactose-inducible promoters. The models would increase their significance if they were based on continuous and tightly regulated gene expression systems for both activation and levels of expression. This would allow for more chronic cytotoxicity that better simulates the timing of events that occur during disease progression. Additionally, the use of metabolism-independent inducers would allow for the study of cell toxicities under conditions where the cells are forced to exclusively respire, thus more reliably modeling the highly oxidative neuronal metabolism. Here we have constructed yeast models of Huntington's disease based on the expression, under the control of different promoters, of the first exon of the huntingtin-containing polyglutamine tracts of both wild-type and mutant lengths. The different models are compared and evaluated.

UR - http://www.scopus.com/inward/record.url?scp=70449351425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449351425&partnerID=8YFLogxK

U2 - 10.2144/000112746

DO - 10.2144/000112746

M3 - Article

VL - 45

SP - 7

EP - 13

JO - BioTechniques

JF - BioTechniques

SN - 0736-6205

IS - 4

ER -